Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Electrochemotherapy with bleomycin for basal cell carcinomas: a systematic review

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Topical corticosteroids reduce the density of Staphylococcus aureus in hand eczema

    Research output: Contribution to journalLetterResearchpeer-review

  3. Effective clinical study recruitment of patients with atopic dermatitis through social media

    Research output: Contribution to journalLetterResearchpeer-review

  1. Needle-free jet injection-induced small-droplet aerosol formation during intralesional bleomycin therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Laser immunotherapy: A potential treatment modality for keratinocyte carcinoma

    Research output: Contribution to journalReviewResearchpeer-review

  5. Delineating papillary dermis around basal cell carcinomas by high and ultrahigh resolution optical coherence tomography-A pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Basal cell carcinoma (BCC) is the most common type of cancer and an increasing incidence stimulates the interest in new treatments such as electrochemotherapy (ECT) with bleomycin. This systematic review focuses on literature from the MEDLINE, Embase, Web of Science, and Cochrane databases. Bleomycin-ECT studies (n = 32) were sorted by the level of evidence adjusted for their BCC data only. The studies included a single randomised controlled trial (RCT), 15 uncontrolled clinical trials, three registry studies, six prospective case series and seven retrospective case series. A Cochrane risk-of-bias assessment of the RCT identified some minor concerns but no predicted risk of bias. The studies were also grouped by bleomycin administration routes: intravenous (n = 14), intralesional (n = 9) and mixed reporting/usage (n = 9). A meta-analysis was not conducted due to the lack of RCTs and the heterogeneity of the included studies. The results of the RCT generally reflected the findings of the other included studies and showed a 92% complete response in 65 bleomycin-ECT-treated BCCs after 2 months, improving to 100% after re-treatment, with a low risk of recurrence. Based on the RCT results and overall data, future studies on BCC treatment with bleomycin-ECT should include large RCTs that compare bleomycin-ECT with standard of care, cost analyses, and clinical feasibility.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume35
Issue number11
Pages (from-to)2208-2215
Number of pages8
ISSN0926-9959
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

© 2021 European Academy of Dermatology and Venereology.

    Research areas

  • Bleomycin/therapeutic use, Carcinoma, Basal Cell/drug therapy, Electrochemotherapy, Humans, Neoplasm Recurrence, Local, Randomized Controlled Trials as Topic, Skin Neoplasms/drug therapy

ID: 72971379